Calimmune

Calimmune is a clinical-stage gene therapy company. The company's lead therapeutic candidate is a gene-based therapy designed to control HIV infection and protect individuals infected with HIV from developing AIDS. This therapy is currently being evaluated in a Phase I/II study. Cal-1 is designed to reduce the production of CCR5, a protein on the surface of white blood cells that plays a critical role in enabling HIV to infect cells. It also incorporates a second mechanism aimed at preventing viral fusion, the process by which the virus enters cells. In preclinical studies, this dual approach has been shown to effectively combat a broad range of HIV strains.